Jodi B. Segal, MD, MPH

home / authors / jodi-b-segal-md-mph

Articles

September 8th 2020

Predictors of Orphan Drug Coverage Restrictions in Medicare Part D

Farah Yehia, PhD Jodi B. Segal, MD, MPH Gerard F. Anderson, PhD

The majority of orphan drugs are subject to utilization controls in Medicare Part D plans. The use of utilization controls varies by certain drug characteristics.

July 19th 2013

Change in Claims-Based Diabetes Medications Is a Diabetes Improvement Indicator

Hsien-Yen Chang, PhD Thomas M. Richards, MS Jeanne M. Clark, MD, MPH Jonathan P. Weiner, DrPH Jodi B. Segal, MD, MPH

Without clinical information, a decrease in use of medications can serve as a proxy for clinical improvement.

November 20th 2012

Validating the Adapted Diabetes Complications Severity Index in Claims Data

Hsien-Yen Chang, PhD Jonathan P. Weiner, DrPH Thomas M. Richards, MSEE Sara N. Bleich, PhD Jodi B. Segal, MD, MPH

The aDCSI without the inclusion of laboratory data performs similarly to the DCSI with laboratory results, and is a good measure of diabetes severity.

April 23rd 2012

Predicting Costs With Diabetes Complications Severity Index in Claims Data

Hsien-Yen Chang, PhD Jonathan P. Weiner, DrPH Thomas M. Richards, MS Sara N. Bleich, PhD Jodi B. Segal, MD, MPH

The Diabetes Complications Severity Index without laboratory test results is a good measure of diabetes severity, given its ability to explain costs.